Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro successfully implanted the first WATCHMAN FLX Pro Device on April 1. MCH ...

Please provide your email address to receive an email when new articles are posted on . In a real-world analysis of registry data, researchers also found that the Watchman FLX device (Boston ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

Please provide your email address to receive an email when new articles are posted on . In a head-to-head comparison of two left atrial appendage closure devices for patients with atrial fibrillation, ...

Results of the Embolic Protection in Patients with Atrial Fibrillation (PROTECT-AF) showed that in AF patients who were candidates for warfarin therapy, device closure of the LAA using the Watchman ...

(UPDATED) In patients undergoing left atrial appendage (LAA) occlusion, the Amplatzer Amulet device (Abbott) provides better closure as well as noninferior safety and effectiveness compared with the ...

Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial ...

Sophia Antipolis, France – 30 Aug 2021: The Amplatzer Amulet Left Atrial Appendage Occluder has shown superior left atrial appendage (LAA) closure and noninferior safety and effectiveness for stroke ...

ABBOTT PARK, Ill., Aug. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company ...